ArticleBioanalysis2025
Addressing nonspecific interactions in a Gyrolab anti-drug antibody (ADA) assay: a case study on method optimization to improve repeatability.
Article in Bioanalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimAnti-drug antibodies (ADAs) can impact drug efficacy and safety, necessitating sensitive and drug-tolerant assays for accurate detection. The main goal of the study was re-optimization of the Gyrolab immunoassay intended to detect ADAs against MabionCD20 (rituximab biosimilar) in rheumatoid arthritis patient serum. The study focused on eliminating a nonspecific interaction that impacted assay repeatability.
resultsThe nonspecific interactions were mitigated by evaluating numerous method modification strategies including additional washing steps, increasing buffer ionic strength, and step-by-step modification of the assay protocol to isolate the one responsible for the observed issue. Reducing molarity and increasing pH of neutralization buffer resulted in elimination of unwanted interactions between assay components and effectively improved assay performance in repeatability and drug tolerance parameters, supporting the assay's suitability for validation.
conclusionCareful optimization of assay conditions, particularly buffer composition and pH successfully resolved issues related to the nonspecific interactions and enhanced assay robustness. Optimized Gyrolab-based immunoassay provided a reliable method for ADA detection, supporting immunogenicity assessment in a clinical development program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.